anlotinib + cadonilimab + docetaxel

This is a combination regimen of three agents used in oncology clinical trials and investigational settings: **Anlotinib** is a novel oral multi-target tyrosine kinase inhibitor that blocks several receptor tyrosine kinases involved in tumor angiogenesis and proliferation, including vascular endothelial growth factor receptors 2 and 3 (VEGFR2/3), fibroblast growth factor receptors 1–4 (FGFR1–4), platelet-derived growth factor receptors α and β (PDGFRα/β), c-Kit, and Ret. It inhibits tumor angiogenesis, cell migration, proliferation, and survival[2][3][5]. **Cadonilimab** is a bispecific monoclonal antibody targeting both programmed cell death protein 1 (PD‑1) and cytotoxic T lymphocyte-associated antigen 4 (CTLA‑4). It acts as a dual immune checkpoint inhibitor to enhance anti-tumor immune responses. **Docetaxel** is a well-established chemotherapeutic agent classified as a taxane. It promotes microtubule assembly while inhibiting disassembly, thereby disrupting mitosis and inducing apoptosis in cancer cells. The combination aims to leverage the antiangiogenic effects of anlotinib with the immunomodulatory activity of cadonilimab plus the cytotoxic action of docetaxel for synergistic antitumor efficacy. This regimen has been investigated primarily for advanced or refractory solid tumors such as non-small cell lung cancer.

Brand names

Focus V

Other names

anlotinib dihydrochlorideAL3818AL-3818AL 3818AK104AK-104AK 104Taxotere